The addition builds on Artera’s inclusion in the guidelines for localized prostate cancer, extending decision support to patients with recurrent disease following radical prostatectomy

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the ArteraAI Prostate Test (Post-RP) has been included in the updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Prostate Cancer (Version 1.2027), as a risk stratification tool for patients experiencing biochemical recurrence (BCR) following radical prostatectomy.

Artera’s tests are the only AI-based risk stratification tools included in the NCCN Guidelines for Prostate Cancer, and one of only two tests included across three patient groups: intermediate-risk, high-risk, and biochemical recurrence. The update builds on the 2024 inclusion of the ArteraAI Prostate Test in the guidelines for localized prostate cancer.

An estimated 20% to 40% of patients who undergo radical prostatectomy eventually develop BCR, indicated by a rising PSA level that can signal the cancer has returned. Clinicians must then weigh whether to add hormone therapy to salvage radiation, a decision with important implications for treatment benefit and quality of life.

The ArteraAI Prostate Test (Post-RP) analyzes digitized surgical pathology images and clinical data, without requiring additional tissue, to stratify patients by risk of disease progression and help inform treatment decisions for patients experiencing BCR following radical prostatectomy.

“Artera’s technology supports treatment decisions at multiple points in prostate cancer care,” said Andre Esteva, CEO and co-founder of Artera. “The addition of our test within the NCCN Guidelines for use in the post-RP salvage setting reinforces the role of AI-powered insights in helping clinicians make more personalized, evidence-based treatment decisions throughout a patient’s cancer journey.”

Commercially available since December 2025, the ArteraAI Prostate Test (Post-RP) is supported by validation data published in European Urology and first presented at the 2024 American Urological Association (AUA) Annual Meeting, demonstrating its ability to stratify patients by metastasis risk and identify those more likely to benefit from adding hormone therapy to salvage radiation. The test has also been externally validated in institutional cohorts from the University of California, San Francisco and Mayo Clinic.

About Artera

Artera is a global leader in precision medicine, leveraging multimodal artificial intelligence (MMAI) to personalize cancer care. Artera’s MMAI platform leverages a patient’s digitized histopathology images along with the patient’s clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials across different cancers and is available in multiple versions across the globe.

Artera’s FDA-authorized software products include ArteraAI Prostate (de novo authorization) and ArteraAI Breast (510(k) clearance). In addition, Artera has received CE Marking for its prostate and breast cancer in vitro diagnostic tests, supporting regulated availability in international markets.

Artera’s flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the US and internationally through its distribution partners. The ArteraAI Prostate Test is the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions.

Artera’s headquarters is based in Los Altos, California, while its CLIA-certified and clinical laboratory is located in Jacksonville, Florida. For more information about Artera, visit artera.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261111174649/en/